Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies

Agnieszka Tomaszewska, Madan Jagasia, Eric Beohou, Steffie van der Werf, Didier Blaise, Edward Kanfer, Noel Milpied, Péter Reményi, Fabio Ciceri, Jean H Bourhis, Patrice Chevallier, Carlos Solano, Gerard Socié, Benedetto Bruno, Alessandro Rambaldi, Luca Castagna, Nicolaus Kröger, Paolo Corradini, Boris Afanasyev, Marco LadettoDietger Niederwieser, Christof Scheid, Henrik Sengeloev, Frank Kroschinsky, Ibrahim Yakoub-Agha, Helene Schoemans, Christian Koenecke, Olaf Penack, Zinaida Perić, Hildegard Greinix, Rafael F Duarte, Grzegorz W Basak

2 Citations (Scopus)

Abstract

Rituximab (R) is increasingly incorporated in reduced intensity conditioning (RIC) regimens for allogeneic hematopoietic cell transplantation (alloHCT) in patients with B-cell malignancies, not only to improve disease control, but also to prevent graft-versus-host disease (GVHD). There are no randomized prospective data to validate this practice, although single center data and the CIBMTR analysis have shown promising results. We aimed at validation of these findings in a large registry study. We conducted a retrospective analysis using the EBMT registry of 3,803 adult patients with B-cell malignancies undergoing alloHCT (2001-2013) with either rituximab (R-RIC-9%) or non-rituximab (RIC-91%) reduced intensity regimens respectively. Median age and median follow up were 55 years (range 19.1-77.3) and 43.2 months (range 0.3-179.8), respectively. There was no difference in transplant outcomes (R-RIC vs RIC), including 1-year overall survival (69.9% vs 70.7%), 1-year disease-free survival (64.4% vs 62.2%), 1-year non-relapse mortality (21% vs 22%), and day-100 incidence of acute GVHD 2-4° (12% vs 12%). In summary, we found that addition of rituximab in RIC regimens for B-cell malignancies had no significant impact on major transplant outcome variables. Of note, data on chronic GVHD was not available, limiting the conclusions that can be drawn from the present study.

Original languageEnglish
Article number613954
JournalFrontiers in Immunology
Volume11
Pages (from-to)613954
ISSN1664-3224
DOIs
Publication statusPublished - 2 Feb 2021

Keywords

  • Adult
  • Aged
  • B-Lymphocytes/drug effects
  • Disease-Free Survival
  • Female
  • Graft vs Host Disease/etiology
  • Hematopoietic Stem Cell Transplantation/methods
  • Humans
  • Leukemia, B-Cell/drug therapy
  • Lymphoma, B-Cell/drug therapy
  • Male
  • Middle Aged
  • Neoplasms/drug therapy
  • Registries
  • Rituximab/therapeutic use
  • Transplantation Conditioning/methods
  • Young Adult
  • non-relapse mortality after hematopoietic cell transplantation
  • B-cell malignancy
  • conditioning
  • transplantation
  • graft-versus-host disease
  • rituximab

Fingerprint

Dive into the research topics of 'Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies'. Together they form a unique fingerprint.

Cite this